Abstract

Design, Synthesis and In-Silico Studies of Novel Chalcones as Anti-Prostate Cancer and Cathepsin B InhibitorsDalia Hussein Soliman, Amel Mostafa Farrag, Ola Omran

Highlights

  • The prevalence of prostate cancer (PCa) is increasing in our community

  • Key component relationship between Metabolic syndrome (MetS) and PCa MetS is comprised of high adiposity, hypertension, dyslipidemia, and hyperglycemia that are suspected to play a significant role in the worsening of PCa prognosis (Figure 3)

  • Glucose levels at the time of PCa diagnosis are suggested to be an independent predictor of PCa recurrence. These findings suggest that there is some relationship between MetS with PCa development that warrants our attention

Read more

Summary

INTRODUCTION

The prevalence of prostate cancer (PCa) is increasing in our community. In Asian regions, the incidence of PCa has been on the rise from 5% in 1978 to 118% in 1997 in the indexed countries (Sim and Cheng, 2005), and there is no sign of this trend abating. Plant-derived leptin antagonist, honokiol, has been discovered from Magnolia grandiflora It can negatively mediate the growth of breast cancer cells by inhibiting leptin-induced epithelial–mesenchymal transition (EMT) and mammosphere formation along with a reduction in the expression of stemness factors (Avtanski et al, 2015). Apart from that, resveratrol has been reported to reduce leptin expression from isolated rat adipocytes (Szkudelska et al, 2009) This finding provides great insight into the potential of plant-derived bioactive compounds as one of the treatment strategies of PCa. This finding provides great insight into the potential of plant-derived bioactive compounds as one of the treatment strategies of PCa With these insights, the therapeutic potential of plant phytochemicals has been gaining more research attention. AP is an herb with high potential for the treatment of PCa–MetS codisease

METHODOLOGY
RESULT & DISCUSSION
Method
Limitation
Findings
CONCLUSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.